<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047019</url>
  </required_header>
  <id_info>
    <org_study_id>14727</org_study_id>
    <secondary_id>2012-004493-26</secondary_id>
    <nct_id>NCT02047019</nct_id>
  </id_info>
  <brief_title>Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects With Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the efficacy and safety of the Fixed Dose combination BAY98-7106
      (nifedipine plus candesartan) in patients with hypertension, who do not achieve adequate
      control of blood pressure with candesartane alone.

      Patients meeting the entry criteria, will receive candesartan alone 16mg in the first five
      weeks of the study to assess blood pressure control with candesartan given alone.

      Patients with an insufficient therapeutic response to candesartan alone (defined by mean
      seated systolic blood pressure &gt;/=140 mm/Hg) will enter the next part of the study, and will
      be randomly assigned to one of 3 treatments ( candesartan alone 16mg, combination nifedipine
      / candesartan 30/16 mg, combination nifedipine / candesartan 60/16 mg). Neither patient nor
      the treating physician will know which treatment is given (double-blinded design).This part
      of the study will last eight weeks.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    GPDC decided to terminate the study
  </why_stopped>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 8, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean seated systolic blood pressure (MSSBP).</measure>
    <time_frame>From baseline to treatment week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean seated diastolic blood pressure (MSDBP).</measure>
    <time_frame>From baseline to treatment week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure Response Rate</measure>
    <time_frame>Treatment week 8</time_frame>
    <description>Response rate is defined as the percentage of subjects achieving a systolic blood pressure (SBP) response (MSSBP of &lt; 140 mmHg or a reduction of MSSBP of &gt; 20 mm Hg from baseline value), or a diastolic blood pressure (DBP) response (i.e. MSDBP of &lt; 90 mmHg or a reduction of MSDBP of &gt; 10 mm Hg from baseline value) after 8 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure Control Rate</measure>
    <time_frame>Treatment week 8</time_frame>
    <description>Control rate is the percentage of subjects that reach the predetermined blood pressure(BP) target &lt; 140/90 mmHg. In addition, the percentage of subjects that reach the predetermined BP target &lt; 140/90 mmHg for subjects without diabetes or chronic renal disorder(baseline estimated glomerular filtration rate(GFR) &lt; 60 mL/min); &lt;130/80 mmHg for subjects with diabetes or chronic renal disorder will be provided as well.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in systolic blood pressure and diastolic blood pressure in ambulatory blood pressure monitoring over 24 hours.</measure>
    <time_frame>Treatment week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>Treatment week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine/Candesartan-30/16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine/Candesartan-60/16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)</intervention_name>
    <description>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily</description>
    <arm_group_label>Nifedipine/Candesartan-30/16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)</intervention_name>
    <description>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily</description>
    <arm_group_label>Nifedipine/Candesartan-60/16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>Candesartan Cilexetil, 16 mg, capsule, orally, once daily</description>
    <arm_group_label>Candesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan matching placebo</intervention_name>
    <description>Candesartan matching placebo, capsule, orally, once daily</description>
    <arm_group_label>Nifedipine/Candesartan-30/16</arm_group_label>
    <arm_group_label>Nifedipine/Candesartan-60/16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo</intervention_name>
    <description>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily</description>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_label>Nifedipine/Candesartan-60/16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)</intervention_name>
    <description>Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily</description>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_label>Nifedipine/Candesartan-30/16</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

          -  Male and female subjects 18 years or older are eligible.

          -  At Visit 0, subjects not treated with antihypertensive medications are to have MSSBP
             (mean seated systolic blood pressure) of &gt;/= 160 mmHg and &lt; 200 mmHg, and 24 hours
             MASBP (mean ambulatory systolic blood pressure) &gt;/= 130 mmHg; those subjects treated
             with antihypertensive medication are to have MSSBP &gt;/= 150 mmHg and &lt; 200 mmHg as
             measured by a calibrated electronic BP measuring device

          -  At Visit 3,subject must have MSSBP &gt;/= 140 mmHg before randomization.

          -  Women of childbearing potential and men must agree to use adequate contraception other
             than hormonal contraceptives when sexually active. This applies since signing of the
             IC (informed consent)form until the last study drug administration.

          -  Exclusion Criteria:

          -  Mean seated systolic blood pressure (MSSBP) &gt;/= 200 mmHg and/or mean seated diastolic
             blood pressure (MSDBP) &gt;/= 120 mm/Hg

          -  Mean seated diastolic blood pressure (MSDBP) &lt; 60 mm/Hg

          -  Differences greater than 20 mmHg for systolic blood pressure (SBP) and 10 mmHg for
             diastolic blood pressure (DBP) are present on 3 consecutive blood pressure readings at
             visit 0

          -  Evidence of secondary hypertension such as coarctation of the aorta, pheochromocytoma,
             hyperaldosteronism, etc.

          -  Cerebrovascular ischemic event (stroke, transient ischemic attack [TIA]) within the
             previous 12 months

          -  History of hypertensive retinopathy - known Keith-Wagener Grade III or IV. Any history
             of heart failure, New York Heart Association (NYHA) classification III or IV

          -  Severe coronary heart disease as manifest by a history of myocardial infarction or
             unstable angina in the last 6 months prior to visit 0

          -  Clinically significant cardiac valvular disease

          -  Subjects with an aortic aneurysm that, in the opinion of the investigator, will be
             unsuitable to be enrolled in the study.

          -  Type 1 diabetes mellitus (DM) or poorly controlled Type 2 DM as evidenced by
             glycosylated hemoglobin HbA1C of greater than 9% on visit 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione Università G.D'Annunzio</name>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Bologna Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAS 3 Friuli Alto Medio Collin</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ist Neurologico Mediterraneo</name>
      <address>
        <city>Isernia</city>
        <state>Molise</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Sassari</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AULSS 07 Pieve Soligo</name>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug combination</keyword>
  <keyword>Nifedipine GITS</keyword>
  <keyword>Candesartan Cilexetil</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

